Processes 2019, 7,37
161. D’Esposito, A.; Sweeney, P.W.; Ali, M.; Saleh, M.; Ramasawmy, R.; Roberts, T.A.; Agliardi, G.; Desjardins, A.;
Lythgoe, M.F.; Pedley, R.B.; et al. Computational fluid dynamics with imaging of cleared tissue and of in vivo
perfusion predicts drug uptake and treatment responses in tumours. Nat. Biomed. Eng. 2018, 2, 773–787.
[CrossRef]
162. Stamatelos, S.K.; Kim, E.; Pathak, A.P.; Popel, A.S. A bioimage informatics based reconstruction of breast
tumor microvasculature with computational blood flow predictions. Microvasc. Res. 2014, 91, 8–21.
[CrossRef][PubMed]
163. Kirouac, D.C. How do we “validate” a QSP model? CPT Pharmacometrics Syst. Pharmacol. 2018, 7, 547–548.
[CrossRef]
164. Gadkar, K.; Kirouac, D.; Parrott, N.; Ramanujan, S. Quantitative systems pharmacology: A promising
approach for translational pharmacology. Drug Discov. Today Technol. 2016, 21–22, 57–65. [CrossRef]
165. Workman, P.; Draetta, G.F.; Schellens, J.H.M.; Bernards, R. How much longer will we put up with 100,000
cancer drugs? Cell 2017, 168, 579–583. [CrossRef]
166. Zhang, X.; Li, Y.; Pan, X.; Xiaoqiang, L.; Mohan, R.; Komaki, R.; Cox, J.D.; Chang, J.Y. Intensity-modulated
proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or
passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB
non-small-cell lung canc. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77, 357–366. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
63